Modality
Radioligand
MOA
CAR-T CD19
Target
TYK2
Pathway
PD-1/PD-L1
SMACMLMS
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
Sep 2018
→ Apr 2030
Phase 3Current
NCT04670920
1,474 pts·CML
2018-09→2030-04·Completed
NCT08641505
2,846 pts·MS
2022-04→2027-10·Terminated
4,320 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-261.6y awayPh3 Readout· MS
2030-04-154.0y awayPh3 Readout· CML
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2027-10-26 · 1.6y away
MS
Ph3 Readout
2030-04-15 · 4.0y away
CML
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04670920 | Phase 3 | CML | Completed | 1474 | VA |
| NCT08641505 | Phase 3 | MS | Terminated | 2846 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| Elracapivasertib | Kymera | Phase 3 | PRMT5 | |
| SND-4562 | Syndax | NDA/BLA | AuroraA |